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http://dx.doi.org/10.1016/j.jfma.201In Taiwan, cervical cancer is ranked sixth among all causes of death in women. With the goal of
reducing the incidence of cervical cancer, the Kinmen County Health Bureau planned to imple-
ment a pilot human papillomavirus (HPV) vaccination program in 2007. The Bureau established
a committee to promote public awareness, coordinate with the schools, arrange for the admin-
istration of the vaccine, establish a vaccination registry, and develop a plan for follow-up and
assessment. Vaccination for female residents aged 16e18 began through a school-based
program in 2008. A total of 1633 girls completed the vaccination protocol within 3 years,
and vaccine uptake rates of over 90% were achieved by 2010. No serious adverse events were
reported among those who were vaccinated. The experience gained from the Kinmen County
HPV vaccination program has helped and will continue to help establish an operational model
for similar programs throughout the country.
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In Taiwan, cervical cancer is ranked sixth among all causes
of death in women, and is the second most frequent cancerInfectious Diseases, Depart-
niversity Hospital, Number 7,
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2.10.004in women aged 15e44.1 In 1995, the Bureau of Health
Promotion initiated a national program of annual Pap
screening for all women over 30 years of age and a national
Pap smear registry was established. The screening program
has resulted in a decrease in the age-standardized inci-
dence rate for invasive cervical cancer from 24 cases per
100,000 women in 1995 to fewer than 13 cases per 100,000
women in 2006, and a marked decrease in the mortality
rate from cervical cancer, from11 deaths per 100,000
women in 1995 to 5.8 deaths per 100,000 women in 2007,
a reduction of 46% and 47% in the incidence of cervical
cancer and its mortality, respectively.2& Formosan Medical Association. All rights reserved.
HPV vaccination in Kinmen, Taiwan 683In the early 1980s, researchers discovered an association
between certain strains of human papillomavirus (HPV) and
cervical cancer. In Taiwan, hospital-based HPV screening
revealed that the most common types of HPV related to
invasive cervical cancer were types 16, 18, 52, and 58.3
HPV vaccines, first approved in the United States in
2006, are expected to prevent an estimated 70% of future
cervical cancer cases,4,5 as well as offer protection against
other HPV-related cancers. Previous studies in Taiwan6e8
have concluded that vaccination is cost-effective in terms
of future expenditures for health care and improvements in
life expectancy. Although universal HPV vaccination will
not reduce the incidence of cervical cancer in the short
term, a decline in the number of cervical cancer cases is
expected some decades from now.
Based on a population dynamic transmission model,
a 91% reduction in HPV 16/18-related cervical cancers from
vaccination was estimated to result in an incremental cost-
effectiveness ratio of New Taiwan Dollar (NTD) 410,477 per
quality-adjusted year of life gained from a vaccination
program targeting women between ages 12 and 24.6,7 This
result is considered to be cost-effective as it is less than the
per capita gross domestic product of NTD 450,000 in 2007.
Other studies have confirmed that vaccination is cost-
effective for girls and young women.9,10
Vaccine uptake is crucial to the success of a publicly
funded HPV vaccination program. Several factors can affect
the rate of public acceptance.11,12 These include public
understanding that vaccination of a healthy person reduces
the risk of that person contracting the disease, ease of
access to vaccination, previous immunization experience,
and parental concern over the sexual implications of HPV
vaccination.13 This article provides an overview about the
establishment and implementation of a public HPV vacci-
nation program in Kinmen County, Taiwan.
Methods
The Kinmen County Health Bureau established an HPV
program committee comprised of internal Bureau officers
and external HPV vaccination-related experts to oversee
the promotion of public awareness, collaboration with the
schools, administration of the vaccine, establishment of
a vaccination registry, and development of plans for follow-
up and assessment.
Promotion of public awareness
A survey by Trim et al showed a high public acceptance rate
for HPV vaccination, with the only major concern being
vaccine safety.14 With existing comprehensive safety and
efficacy data from placebo-controlled phase III studies in
over 18,000 HPV vaccine recipients,15,16 the committee
developed a communication strategy to disseminate this
safety and efficacy information. The committee organized
11 educational events, inviting the general public, women’s
rights advocacy group leaders, health-care practitioners,
government officials, and school teachers to participate in
informational sessions led by gynecologic oncology experts.
In addition, the committee developed a series of public
awareness programs, including (1) interviews featuringgynecologic oncologists and pediatric infection specialists
broadcast on Kinmen County television stations; (2) public
service messages featuring the voice of the chief of the
Kinmen County Health Bureau broadcast on national radio
programs; (3) school-based, face-to-face health education
lectures; (4) posters and banners displayed in schools,
health clinics, hospitals, and government offices; (5) large
and frequent advertisements in Kinmen County newspa-
pers. All of these efforts focused on educating the public
about the prevalence of HPV, its role in the development of
cancer, the safety of the vaccine, and the optimal age for
vaccination. Details about the free vaccination program
provided by the Kinmen County government were also
provided.
Target population
A previous survey in Taiwan had indicated that girls’
average age of becoming sexually active was 16.15 years
and that 10.4% of adolescent girls were sexually active.17
Optimally, HPV vaccination should be completed before
sexual activity starts; however, to avoid potential parental
objection to vaccinating the very young cohort due to the
sexual connotation of HPV vaccination, the Kinmen County
Health Bureau established a 3-year vaccination program
targeting all high-school girls between 16 and 18 years of
age. This age group was targeted as the priority cohort
because they needed to be protected more urgently than
did the younger junior high-school cohort of 13e15 year
olds. This cohort was also more readily accessible through
a school-based network compared with the older catch-up
cohort of women up to 26 years of age who could be
accessed primarily through a community-based health-care
network.
Vaccine administration
A vaccination schedule was constructed for the administra-
tion of the first, second, and third doses of the HPV vaccine in
each high school in the county. Administration of the vaccine
was carried out by qualified medical practitioners following
the public vaccination standard procedure issued by the
Centers for Disease Control, Taiwan. Body temperature was
measured before vaccine administration. Those presenting
with fever (>38.5C) or other signs of illness were not
vaccinated and were instructed to receive vaccination from
a primary health-care provider once the symptoms have
subsided.Thosewhowerevaccinated remained seated in the
health station under the supervision of the physician and
nurses for at least 30 minutes. Any adverse events reported
by the vaccine recipient or observed by the practitionerwere
recorded and managed accordingly. A postvaccination
educational card was given to each student who was vacci-
nated, which reminded them to report any event occurring
during the next 7 days. The vaccine was administered free of
charge to eligible recipients.
Assessments
The committee established a mandatory registry to docu-
ment the name of the vaccine recipient, vaccination date,
Table 1 Vaccine uptake rates.
Year Age of
cohort (y)
Eligible vaccine
recipients (n)
First dose
uptake rate [% (n)]
Second dose
uptake rate [% (n)]
Third dose
uptake rate [% (n)]
2008 16e18 1438 66 (949) 64 (920) 63 (906)
2009 16 368 92 (339) 89 (328) 86 (317)
2010 16 379 91 (345) 91 (345) 89 (337)
684 C.-C. Lee et al.vaccine batch number, and any adverse event occurring
while administering the vaccine. This would enable the
detection of short-term safety and tolerability issues and
facilitate long-term follow-up.
To evaluate public perception of the program, a post-
vaccination survey was mailed to the target population and
their parents after the first pilot cohort was completed in
2008. The objective of the survey was to evaluate parental
acceptance of the new vaccine, reasons for not receiving
vaccine, and the impact of HPV disease knowledge level on
vaccine acceptance.Results
The first cohort of 16e18-year-old girls in 2008 resulted in
a 66% uptake rate of the first dose. The subsequent vaccine
administration to 16-year-old female cohorts in 2009 and
2010 resulted in first-dose uptake rates of 92% and 91%,
respectively. In all the three cohorts, approximately 95% of
the girls who had received a first dose completed the full
series of three doses (Table 1).
The postvaccination survey achieved a response rate of
90%. Approximately 70% of the responders had some
knowledge about HPV and its related diseases and 83%
indicated they were very satisfied or satisfied with the new
immunization program. Fig. 1 presents the various reasons
for not receiving the vaccine.
No serious adverse events were reported during the
vaccination period. One vaccine recipient experienced
shortness of breath, flushing, and chills immediately after
the first dose of vaccine, and one recipient experienced
dizziness and fever after the second dose. In both
participants, the symptoms resolved without compli-
cation.Figure 1 Survey results: reasons for not receiving human
papillomavirus (HPV) vaccination. (Respondents could select
more than one reason).Discussion
In Kinmen County, the school-based HPV vaccination uptake
rate increased from 66% in 2008 to over 90% in 2009 and
2010. The lower rate of uptake for the first cohort may have
been attributed to uncertainty surrounding a newly imple-
mented vaccination program. Excellent vaccine safety and
tolerability evidenced in the first cohort may have allevi-
ated public concerns over adverse events from vaccination,
leading to significantly higher uptake rates in the subse-
quent cohorts in 2009 and 2010.
School-based programs have proven to be an effective
approach, as target cohorts can be accessed directly
through the school system and their parents can be easily
contacted for public health education and consent for
vaccination. However, older cohorts would unlikely be
universally reached through a group vaccination approach,
and may need to rely on primary health-care centers for
vaccination. In order to maximize vaccine uptake rate,
increased and focused effort should be placed on vaccina-
tion of the school-age population.
Although the impact of vaccination remains to be
observed over the coming decades, early reductions in the
rate of cervical abnormalities were reported 3 years after
the initiation of the HPV program in Australia.18 One can
confidently predict that, if a high rate of vaccine uptake
and regular Pap screenings can be maintained, the inci-
dence of HPV-related diseases including cervical cancer will
continue to decline over time in Taiwan.
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